UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )*

Skye Bioscience, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

83086J101

(CUSIP Number)

Rebecca Lucia

5AM Venture Management, LLC

501 2nd Street, Suite 350

San Francisco, CA 94107

(415) 993-8565

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 18, 2023

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The class of equity security to which this statement on Schedule 13D relates is the Common Stock, par value $0.001 (“Common Stock”) of Skye Bioscience, Inc., a Nevada corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 11250 El Camino Real, Suite 100, San Diego, CA 92130. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Between December 23, 2008 and October 19, 2016, Ventures II and Co-Investors II purchased an aggregate of 14,417,984 and 568,896 shares of Bird Rock’s preferred common stock at aggregate purchase prices of $16,305,757 and $643,383, respectively.

On August 15, 2023, the Issuer and Bird Rock Bio, Inc. (“Bird Rock”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, on August 18, 2023, a wholly-owned subsidiary of the Issuer merged with and into Bird Rock, with Bird Rock surviving the Merger as a wholly-owned subsidiary of the Issuer (the “Merger”).

At the effective time of the Merger, each outstanding share of Bird Rock’s preferred stock converted into shares of the Issuer’s Common Stock based on an exchange ratio determined in accordance with the Merger Agreement.

In connection with the Merger Agreement, on August 15, 2023, Ventures VII and other unrelated investors entered into a Securities Purchase Agreement with the Issuer (the "Purchase Agreement"), pursuant to which Ventures VII purchased an aggregate of 852,696,240 shares of Common Stock (of which Ventures II and Co-Investors II were allocated 161,944,872 shares and 6,389,921 shares, respectively) for the total purchase price of $8.8 million and received warrants to purchase 426,348,120 shares of Common Stock for no additional consideration (the “PIPE Transaction”). The PIPE Transaction closed concurrently with the Merger on August 18, 2023.

Following the closing of the Merger and the PIPE Transaction, Ventures VII, Ventures II and Co-Investors II directly own 684,361,447, 429,546,911 and 16,948,799 shares of Common Stock, respectively, and Ventures VII directly owns Warrants to purchase 426,348,120 shares of Common Stock.

The source of the funds for the purchases by each of Ventures VII, Ventures II and Co-Investors II described above was from capital contributions made by each of their general and limited partners.

The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer. Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer’s business, prospects and financial condition, the market for the Issuer’s securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons’ ownership of the Issuer’s securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time (including by means of programs adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the “Act”)). Each of the Reporting Persons reserve the right to increase or decrease its holdings on such terms and at such times as each may decide.

Except as set forth in this Item 4 and Item 6 below, none of the Reporting Persons have a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act. However, each of the Reporting Persons reserves the right to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the Common Stock to become eligible for termination of registration under Section 12(g) of the Act. The Reporting Persons also retain the right to change their investment intent at any time, to acquire additional shares of Common Stock or other securities of the Issuer from time to time, or to sell or otherwise dispose of all or part of the Common Stock beneficially owned by them (or any shares of Common Stock into which such securities are converted) in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.

Andrew J. Schwab, a Managing Member of each of Partners VII and Partners II, joined the board of directors of the Issuer concurrently with the closing of the Merger and PIPE Transaction. As a director of the Issuer, Schwab may have influence over the corporate activities of the Issuer, including activities which may relate to the transactions described in clauses (a) through (j) of Item 4 of Schedule 13D.

Registration Rights Agreement

On August 15, 2023, in connection with the execution of the Merger Agreement and the Purchase Agreement, the Issuer entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with certain investors (collectively the “Holders”), including Ventures VII, Ventures II and Co-Investors II, pursuant to which the Issuer has agreed, subject to the terms and conditions of the agreement, to file a registration statement under the Securities Act of 1933 promptly and, in any event, within 180 days from the of the Registration Rights Agreement to register the resale of the shares of Common Stock beneficially owned by the Holders, including all shares of Common Stock held by Ventures VII, Ventures II and Co-Investors II, as well as the shares issuable upon exercise of the Warrants (as defined below) held by Ventures II . The Registration Rights Agreement also includes customary provisions, including with respect to the payment of fees and expenses associated with the registration, as well as indemnification provisions.

The foregoing description is qualified in its entirety by the full text and form of the Registration Rights Agreement, a copy of which is filed herewith as Exhibit B and incorporated herein by reference.

Common Stock Purchase Warrants

The common stock purchase warrants (the “Warrants”) held by Ventures VII are exercisable at any time during the period beginning on August 18, 2023 and ending on August 18, 2033. The exercise price per share of Common Stock under these Warrants is $0.02064041, subject to adjustment as described in the Form of Common Stock Purchase Warrant.

The foregoing description is qualified in its entirety by the full text and form of Warrant, a copy of which is filed herewith as Exhibit C and incorporated herein by reference.

Lock-Up Agreements

Concurrently and in connection with the execution of the Merger Agreement and the Purchase Agreement, certain former stockholders of Bird Rock, certain officers, directors and stockholders of the Issuer immediately prior to the Merger, the investors in the PIPE Transaction (including Ventures VII, Ventures II and Co-Investors II) and an unaffiliated provider of convertible debt to the Issuer entered into separate lock-up agreements with the Issuer, pursuant to which each such party is restricted from selling or transferring any shares of Common Stock held by each such person as of the closing of the Merger and the PIPE Transaction for a period of one year following the closing of the Merger and the PIPE Transaction (the “Lock-Up Agreements”).

The foregoing description is qualified in its entirety by the full text and form of the Lock-Up Agreement, a copy of which is filed herewith as Exhibit D and incorporated herein by reference.

Non-Employee Director Compensation

Schwab, in his capacity as a non-employee director of the Issuer, may be entitled to receive, from time to time, stock options or other awards of equity-based compensation pursuant to the Issuer’s compensation arrangements for non-employee directors.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 28, 2023

Exhibit(s):